Reduction of interstitial fluid retention by combination therapy with dapagliflozin, an SGLT2 inhibitor, and conventional diuretics: comment on a post-hoc analysis of the DAPA-BODY trial

Hypertension Research 2026 Open access

Read full text

Authors: Takuya Tomaru

DOI: 10.1038/s41440-026-02572-1

Cited by: 1

References: 9

Fields of Study & Subjects

Electrolyte and hormonal disorders Diabetes Treatment and Management Ion Transport and Channel Regulation

References 9